Mynd Life Sciences Inc · CSE:MYND
Mynd Life Sciences — Investor Presentation (January 2021)
21 slides from Mynd Life Sciences's investor presentation, January 2021
Slide 1: 2021 Investor Presentation
MYND 2021 Investor Presentation
Slide 2: Disclaimer
Disclaimer Certain information set forth in this presentation contains “forward-looking information”, including “future oriented financial information” and “financial outlook”, under applicable securities laws (collectively referred to herein as forward-looking statements). Except for statements of
Slide 3: Our Founders
Our Founders MYND Life Sciences Inc. was founded by Dr. Wilfred Jefferies and Dr Lyle Oberg with the goal of improving mental health. Dr. Jefferies is a world-renowned Neuroimmunologist with over 60 patents and 100 publications in prestigious medical journals including Nature and The Lancet. Through
Slide 4: Our Mission
Our Mission MYND Life Sciences is a life science , neuro-pharmaceutical drug development company, advancing medicines based on neuron-anti-in ammatory substances through rigorous science and clinical trials with an initial focus on Major Depressive Disorder. Our mission is to further our existing re
Slide 5: Company Highlights
Company Highlights INDUSTRY LEADING WORLD CLASS VERTICAL EXPERIENCED R&D RESEARCH TEAM INTEGRATION MANAGEMENT Psilocybin research license Led by Dr. Wilf Jefferies Collaborating world class Experience in taking orphan granted from Health and his team of PhDs at research facilities at UBC’s and novel
Slide 6: The Problem
The Problem The mental health crisis is currently spiraling out of control. WHO claims depression and anxiety contribute to ~$1T per year in economic costs globally ~13% of people in the United States aged 12+ are currently on anti- depressants with Zoloft being added to the FDA’s list of drugs in s
Slide 7: The Opportunity
The Opportunity The pharmaceutical industry is on the verge of a revolution. $35B Big Pharma has been researching psychedelic compounds as it relates to mental health disorders: Johnson & Johnson created a Ketamine derived nasal spray to treat depression deemed “The first major innovation since Proz
Slide 8: Regulatory Landscape
Regulatory Landscape From a regulatory perspective the ceiling has never been higher for psychedelics. We are seeing a major paradigm shift globally as it relates to psychedelic assisted therapies and research into these molecules. United States • Major cities in Colorado, California, Michigan, Oreg
Slide 9: IP Portfolio
IP Portfolio In 2010 MYND Life Sciences team commenced research on ABCF1, with major breakthroughs related to depression in 2016. Patents Pending Title: A Method of Immune Modulation by Modulating ABCF1 (“Mycogene” Major Depressive Disorder - modulation of Mycogene in the treatment of depression 202
Slide 10: Human Mycogene Program
Human Mycogene Program • Designed to treat neuropsychiatric disorders through the dosing of formulations of psilocybin. The initial indication for the HMM (Human Mycogene Modulation) program was to deal with toxic shock syndrome and sepsis and through years of research and studies on mice which iden
Slide 11: Psychotropic Development Timeline
Psychotropic Development Timeline Dev Stage H2 2020 H1 2021 H2 2021 H1 2022 H2 2022 H1 2023 1. Screening: Identify lead and backup analogs Milestone 1 Commencement of Chemistry, 11 Manufacturing and Controls 2. (CMC) activities & bioanalytical Milestone 2 method development and validation Commenceme
Slide 12: MYND-604 (MDD) - Drug Development Program
MYND-604(MDD) - Drug Development Program MYND-604 is being developed to treat MDD and bring much needed innovation to the antiquated multi-billion dollar SSRI market. Major depressive disorder is a common and severe disorder that is estimated to affect approximately 350 million people globally. The
Slide 13: MYND-778 (Sepsis) - Drug Development Program
MYND-778(Sepsis) - Drug Development Program Sepsis is the body’s extreme response to an infection. It is a life-threatening medical emergency. Sepsis happens when an infection you already have —in your skin, lungs, urinary tract, or somewhere else—triggers a chain reaction throughout your body. With
Slide 14: Our Team
Our TEAM Our team has the necessary expertise to take our drugs through development to commercialization Corporate Dr. Lyle Oberg Dr. Cheryl Pfeifer, PHD Co-Founder and Chief Executive Officer Senior Research Scientist Dr. Wilfred Jefferies Dr. Chaahat SB Singh, PHD Co-Founder and Chief Science Offi
Slide 15: Scientific Advisory Board
Scientific Advisory Board 2021 Investor Presentation 15
Slide 16: Board of Directors
Board of Directors Dr. Wilfred Dr. Lyle Oberg Roslyn Ritchie-Derrien Aaron Bowden, CPA, CA Jefferies Director Director Directo Board Chair Audit Committee Chair Malcom Lavoie John Campbell Directo Directo Governance and Ethics Committee Chair Compensation Committee Chair 2021 Investor Presentation 1
Slide 17: Competitive Landscape
Competitive Landscape MYND Life Sciences Compass Pathway Mind Medicine Cybin Field Trip Numinus Wellness Tryp Therapeutics BetterLife Pharma Public/Private Private Public Public Private Public Public Public Public CEO Dr. Lyle Oberg George Goldsmith JR Rahn Doug Drysdale Joseph Del Moral Payton Nyqu
Slide 18: For a piece of MYND, call 1.780.965.0122
For a piece of MYND, call 1.780.965.0122
Slide 19: Appendix A: Bios
APPENDIX A: BIOS Dr. Lyle Oberg, Co-Founder and Chief Executive Officer Jordan Cleland, Chief Operating Officer Dr. Wilfred Jefferies Chief Science Officer A physician by profession, Dr. Oberg possesses extensive Jordan Cleland is the Chief Operating Officer of MYND Dr. Wilfred Jefferies is the Co-F
Slide 20: Appendix A: Bios
APPENDIX A: BIOS Dr. Chaahat SB Singh, Senior Research Manager Dr Cheryl Pfeifer, PhD, Senior Research Scientist Marie Johns, Research Manager Dr. Chaahat SB Singh has had training in microbiology, Dr. Cheryl Pfeifer has been involved with Marie is an incoming Medical Gene cs M.Sc. candidate who inf
Slide 21: Appendix A: Bios
APPENDIX A: BIOS Advisory Dan Kriznic CPA, Financial Advisor Sean Power, CPA, U.S. Capital Markets Advisor Dan Kriznic has founded and co-founded a number of Highly accomplished, results driven professional with 16+ years successful public companies in emerging markets. of experience in financial le
MYND Life Sciences — Investor Presentation (January 2021) on 6ix